Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib

E-ISSN： 1097-0142|120|15|2325-2333

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.15, 2014-08, pp. : 2325-2333

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial

By Majer I. M. Gelderblom H. van den Hout W. B. Gray E. Verheggen B. G.

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1106-1119

Informa Healthcare

Access to resources Recommend Favorite

Imatinib‐induced agranulocytosis in patients with gastrointestinal stromal tumors

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 8, 2015-08 ,pp. : 920-925

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor

Oncology, Vol. 76, Iss. 5, 2009-03 ,pp. : 326-332

Karger

Access to resources Recommend Favorite

Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving ImatinibMesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor

Case Reports in Oncology, Vol. 6, Iss. 1, 2013-03 ,pp. : 134-142

Karger

Access to resources Recommend Favorite

Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor

Oncology, Vol. 90, Iss. 2, 2016-0 ,pp. : 112-117

Karger

Access to resources Recommend Favorite